Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis

Leuk Lymphoma. 2017 Feb;58(2):457-460. doi: 10.1080/10428194.2016.1190977. Epub 2016 Jun 7.

Authors

Abdurrahman M Hamadah¹, Gita Thanarajasingam², Kamel A Gharaibeh¹, Heidi D Finnes², Carrie A Thompson², Nelson Leung¹

Affiliations

¹ a Division of Nephrology and Hypertension , Mayo Clinic , Rochester , MN , USA.
² b Division of Hematology , Mayo Clinic , Rochester , MN , USA.

PMID: 27268591
DOI: 10.1080/10428194.2016.1190977

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage*
Antineoplastic Agents, Alkylating / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / administration & dosage*
Cyclophosphamide / adverse effects
Female
Follow-Up Studies
Humans
Kidney Failure, Chronic / complications*
Kidney Failure, Chronic / therapy*
Lymphoma / complications*
Lymphoma / diagnosis
Lymphoma / drug therapy*
Lymphoma / mortality
Male
Middle Aged
Neoplasm Grading
Renal Dialysis*
Treatment Failure
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Cyclophosphamide